Cargando…
Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain
Choroidal neovascularization (CNV) is a key pathological feature of several leading causes of vision loss including neovascular age-related macular degeneration. Here, we show that a calreticulin anti-angiogenic domain (CAD)-like peptide 27, CAD27, inhibited in vitro angiogenic activities, including...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213176/ https://www.ncbi.nlm.nih.gov/pubmed/30274378 http://dx.doi.org/10.3390/ijms19102993 |
_version_ | 1783367709752295424 |
---|---|
author | Bee, Youn-Shen Ma, Yi-Ling Chen, Jinying Tsai, Pei-Jhen Sheu, Shwu-Jiuan Lin, Hsiu-Chen Huang, Hu Liu, Guei-Sheung Tai, Ming-Hong |
author_facet | Bee, Youn-Shen Ma, Yi-Ling Chen, Jinying Tsai, Pei-Jhen Sheu, Shwu-Jiuan Lin, Hsiu-Chen Huang, Hu Liu, Guei-Sheung Tai, Ming-Hong |
author_sort | Bee, Youn-Shen |
collection | PubMed |
description | Choroidal neovascularization (CNV) is a key pathological feature of several leading causes of vision loss including neovascular age-related macular degeneration. Here, we show that a calreticulin anti-angiogenic domain (CAD)-like peptide 27, CAD27, inhibited in vitro angiogenic activities, including tube formation, migration of endothelial cells, and vascular sprouting from rat aortic ring explants. In a rat model of laser-induced CNV, we demonstrate that intravitreal injection of CAD27 significantly attenuated the formation of CNV lesions as measured via fundus fluorescein angiography and choroid flat-mounts (19.5% and 22.4% reductions at 10 μg and 20 μg of CAD27 injected, respectively). Similarly, the reduction of CNV lesions was observed in rats that had received topical applications of CAD27 (choroid flat-mounts: 17.9% and 32.5% reductions at 10 μg/mL and 20 μg/mL of CAD27 instilled, respectively). Retinal function was unaffected, as measured using electroretinography in both groups receiving interareal injection or topical applications of CAD27 for at least fourteen days. These findings show that CAD27 can be used as a potential therapeutic alternative for targeting CNV in diseases such as neovascular age-related macular degeneration. |
format | Online Article Text |
id | pubmed-6213176 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62131762018-11-14 Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain Bee, Youn-Shen Ma, Yi-Ling Chen, Jinying Tsai, Pei-Jhen Sheu, Shwu-Jiuan Lin, Hsiu-Chen Huang, Hu Liu, Guei-Sheung Tai, Ming-Hong Int J Mol Sci Article Choroidal neovascularization (CNV) is a key pathological feature of several leading causes of vision loss including neovascular age-related macular degeneration. Here, we show that a calreticulin anti-angiogenic domain (CAD)-like peptide 27, CAD27, inhibited in vitro angiogenic activities, including tube formation, migration of endothelial cells, and vascular sprouting from rat aortic ring explants. In a rat model of laser-induced CNV, we demonstrate that intravitreal injection of CAD27 significantly attenuated the formation of CNV lesions as measured via fundus fluorescein angiography and choroid flat-mounts (19.5% and 22.4% reductions at 10 μg and 20 μg of CAD27 injected, respectively). Similarly, the reduction of CNV lesions was observed in rats that had received topical applications of CAD27 (choroid flat-mounts: 17.9% and 32.5% reductions at 10 μg/mL and 20 μg/mL of CAD27 instilled, respectively). Retinal function was unaffected, as measured using electroretinography in both groups receiving interareal injection or topical applications of CAD27 for at least fourteen days. These findings show that CAD27 can be used as a potential therapeutic alternative for targeting CNV in diseases such as neovascular age-related macular degeneration. MDPI 2018-09-30 /pmc/articles/PMC6213176/ /pubmed/30274378 http://dx.doi.org/10.3390/ijms19102993 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bee, Youn-Shen Ma, Yi-Ling Chen, Jinying Tsai, Pei-Jhen Sheu, Shwu-Jiuan Lin, Hsiu-Chen Huang, Hu Liu, Guei-Sheung Tai, Ming-Hong Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain |
title | Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain |
title_full | Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain |
title_fullStr | Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain |
title_full_unstemmed | Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain |
title_short | Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain |
title_sort | inhibition of experimental choroidal neovascularization by a novel peptide derived from calreticulin anti-angiogenic domain |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213176/ https://www.ncbi.nlm.nih.gov/pubmed/30274378 http://dx.doi.org/10.3390/ijms19102993 |
work_keys_str_mv | AT beeyounshen inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain AT mayiling inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain AT chenjinying inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain AT tsaipeijhen inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain AT sheushwujiuan inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain AT linhsiuchen inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain AT huanghu inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain AT liugueisheung inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain AT taiminghong inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain |